The Joint Corp.

NASDAQ:JYNT

Medical - Care Facilities

Healthcare
$6.65 +1.86%

+$0.17 today

Market cap
$91.03M
Beta
1.10
P/E (TTM)
40.7
EPS (TTM)
$0.23
52W Low $7.50High $13.00

Volume 0.05M

Average 0.07M

JYNT Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

The Joint Corp.NASDAQ: JYNT

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables grows, but more slowly than its trailing trend

Q1 FY2026 accounts payables of $678.73K (cash outflow) rose 40.9% year over year, behind the +812.5% change in trailing-twelve-month accounts payables.

Context

  • Accounts payables amounted to 0.7% of revenue in FY2025, up 0.6 pp from a year earlier.
  • Accounts payables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +40.9% toward the trailing-twelve-month pace of +812.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$678.73K-362.3% QoQ
Last fiscal yearDec 2025
-$391.13K-673.0% YoY
LTMMar 2026
-$588.3K+812.5% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+40.9%——
1 year-673.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
(391.13K) USD
Year-over-year change
-673.0%

Accounts Payables vs competitors

How JYNT compares with its peers on the latest reported figures

  • JYNT's LTM Mar 2026 accounts payables of $588.3K is the 7th largest of the 11 companies compared; the peer median is $83.5K.
  • Its year-over-year change of +812.5% is the highest of 11, against a peer median of +36.1%.
  • Accounts payables amounts to 1.0% of revenue for JYNT, versus a peer median of 3.9%.
JYNT Competitors Peer median
Accounts Payables for JYNT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DCGODocGo Inc.LTM Mar 2026$7.26M +47.4%—2.4%
BTMDbiote Corp.LTM Mar 2026$4.9M +694.8%+34.5%2.6%
CGTXCognition Therapeutics, Inc.LTM Mar 2026$3.99M -200.8%——
CCLDCareCloud, Inc.LTM Mar 2026$3.55M -19.6%—2.9%
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$2.03M +38.0%+2.5%5.9%
STSSSkyAI, Inc.LTM Mar 2026$1.33M +472.5%—334.6%
JYNTThe Joint Corp.LTM Mar 2026$588.3K +812.5%—1.0%
APYXApyx Medical CorporationLTM Mar 2026$275K +34.1%+74.3%0.5%
LUCDLucid Diagnostics Inc.LTM Mar 2026$250K +278.6%-15.3%4.9%
IKTInhibikase Therapeutics, Inc.LTM Mar 2026$104.75K -122.1%+33.7%—
SERASera Prognostics, Inc.LTM Mar 2026$83K -83.9%—145.6%
Peer median (excluding JYNT) $83.5K+36.1%+33.7%3.9%

Competitors are the stored peer set for JYNT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income7.57M626.71K(9.75M)(8.53M)2.91M
Depreciation & Amortization3.92M6.65M8.58M4.72M1.71M
Deferred Income Tax(1.78M)(441.35K)10.9M(55.56K)93.07K
Stock-Based Compensation1.06M1.27M1.74M1.68M1.3M
Change in Working Capital3.09M(238.06K)798.62K1.1M(9.56M)
Accounts Receivables(1.64M)(154.67K)192.35K(1.65M)1.53M
Inventory00000
Accounts Payables(14.37K)818.27K(1.38M)68.26K(391.13K)
Other Working Capital4.74M(901.65K)1.99M2.68M(10.7M)
Other Non-Cash Items(7.77K)341.68K2.41M10.5M5.39M
Operating Cash Flow13.84M8.21M14.68M9.42M1.84M
Capital Expenditures(6.99M)(5.9M)(5M)(1.19M)(1.5M)
Acquisitions (Net)(5.77M)(12.11M)(1.19M)554.1K7.78M
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0105.2K000
Investing Cash Flow(12.75M)(17.9M)(6.19M)(631.55K)6.27M
Debt Repayment(2.81M)(49.86K)(24.43K)(2.03M)(4.35K)
Common Stock Issued00202.39K33.71K1.52M
Common Stock Repurchased0(5.8K)(3.83K)(9.58K)(11.32M)
Dividends Paid00000
Other Financing Activities811.59K384.27K000
Financing Cash Flow(2M)328.61K174.12K(2M)(9.81M)
Effect of Forex Changes00000
Net Change in Cash(907.29K)(9.36M)8.66M6.78M(1.69M)
Free Cash Flow6.85M2.31M9.68M8.23M334.72K

The Joint Corp.

NASDAQ:JYNT

Intrinsic Alpha fair value

Locked

Current Price

$6.65

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.